Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04400331 · ClinicalTrials.gov registry record · Phase 3
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
A Phase 3 study of Chorea, Huntington, sponsored by Neurocrine Biosciences.
- Active
- Registry status
- Phase 3
- Development phase
- 154
- Enrollment target
- 20
- Study locations
NCT04400331 is a Phase 3 study of Chorea, Huntington that is active but no longer recruiting, run by Neurocrine Biosciences. The registered enrollment target is 154 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT04400331, a Phase 3 study of Chorea, Huntington, is active but no longer recruiting, sponsored by Neurocrine Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 154 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
Conditions Studied
Interventions
- DRUG Valbenazine
Study Locations (20)
Florida
- Neurocrine Clinical Site - Boca Raton
- Neurocrine Clinical Site - Gainesville
Illinois
- Neurocrine Clinical Site - Chicago
- Neurocrine Clinical Site - Chicago
Massachusetts
- Neurocrine Clinical Site - Boston
- Neurocrine Clinical Site - Charlestown
Alabama
- Neurocrine Clinical Site - Birmingham
Arkansas
- Neurocrine Clinical Site - Little Rock
California
- Neurocrine Clinical Site - La Jolla
Colorado
- Neurocrine Clinical Site - Aurora
District of Columbia
- Neurocrine Clinical Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2020-09-18 |
| Est. Completion | 2026-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04400331
The ClinicalTrials.gov registry entry for NCT04400331 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chorea, Huntington appearing as the primary indexed condition, and to 1 intervention - of which Valbenazine is the first listed.
NCT04400331 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Florida, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04400331 about?
NCT04400331 is a clinical study titled "Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease". This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
What is the current status of trial NCT04400331?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 154 participants. The study started on 2020-09-18. Estimated completion is 2026-03.
What conditions does trial NCT04400331 study?
This clinical trial studies the following conditions: Chorea, Huntington.
What interventions are being tested in trial NCT04400331?
The interventions under investigation include: Valbenazine (DRUG).
Who is sponsoring clinical trial NCT04400331?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04400331 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chorea, Huntington
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.